Abstract Background Vascular endothelial growth factor VEGF plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti VEGF agents for the treatment of retinopathy of prematurity ROP , a vasoproliferative disorder. The safety and efficacy of these agents in preterm infants with